Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Cipla
Citi
Medtronic
Fish and Richardson
QuintilesIMS
Teva
Julphar
Argus Health

Generated: November 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021446

« Back to Dashboard

NDA 021446 describes LYRICA, which is a drug marketed by Pf Prism Cv and is included in three NDAs. It is available from ten suppliers. There are six patents protecting this drug and six Paragraph IV challenges. Additional details are available on the LYRICA profile page.

The generic ingredient in LYRICA is pregabalin. There are forty drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the pregabalin profile page.
Summary for 021446
Tradename:LYRICA
Applicant:Pf Prism Cv
Ingredient:pregabalin
Patents:3
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 021446
Suppliers and Packaging for NDA: 021446
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LYRICA pregabalin CAPSULE;ORAL 021446 NDA Parke-Davis Div of Pfizer Inc 0071-1012 0071-1012-68 90 CAPSULE in 1 BOTTLE (0071-1012-68)
LYRICA pregabalin CAPSULE;ORAL 021446 NDA Parke-Davis Div of Pfizer Inc 0071-1013 0071-1013-41 100 CAPSULE in 1 BLISTER PACK (0071-1013-41)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength25MG
Approval Date:Dec 30, 2004TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 22, 2019
Regulatory Exclusivity Use:INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA
Regulatory Exclusivity Expiration:May 3, 2021
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Patent:➤ Sign UpPatent Expiration:Dec 30, 2018Product Flag?Substance Flag?Delist Request?Y
Patented Use:MANAGEMENT OF FIBROMYALGIA

Expired US Patents for NDA 021446

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-003 Dec 30, 2004 ➤ Sign Up ➤ Sign Up
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-008 Dec 30, 2004 ➤ Sign Up ➤ Sign Up
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-001 Dec 30, 2004 ➤ Sign Up ➤ Sign Up
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-005 Dec 30, 2004 ➤ Sign Up ➤ Sign Up
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-006 Dec 30, 2004 ➤ Sign Up ➤ Sign Up
Pf Prism Cv LYRICA pregabalin CAPSULE;ORAL 021446-004 Dec 30, 2004 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Julphar
Johnson and Johnson
Boehringer Ingelheim
McKesson
Chubb
Fuji
Daiichi Sankyo
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.